Butaperazine (Repoise, Tyrylen) is a typical antipsychotic of the phenothiazine class.[2] It was approved in 1967, and possibly discontinued in the 1980s.

Synthesis

Patent:[3]

2-Butyrylphenothiazine [25244-91-1] (1) is the requisite starting material for carrying out the procedure. It is prepared in a manner that is synonymous with the method used in the propiomazine and propiopromazine already discussed. The 1-(γ-chloropropyl)-4-methylpiperazine [104-16-5] (2) is prepared in the conventional way from alkylating 1-methylpiperazine and 1-Bromo-3-chloropropane. Sodamide is used to extract the 10-H thereby facilitating the nucleophilic substitution reaction. And completing the instalment of the sidechain.

See also

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Evaluation of a new antipsychotic agent. Butaperazine maleate (repoise maleate)". JAMA. 206 (10): 2307–8. December 1968. doi:10.1001/jama.206.10.2307. PMID 4386884.
  3. ^ Dr Ulrich Hoerlein, Dr Klaus-Heinz Risse, Dr Wolfgang Wirth, DE 1120451  (1961 to Bayer Ag).